Brief: Transgene Reports Results From Clinical Study Of TG4001 With avelumab

Transgene SA

22/07/2020 15:51

July 22 (Reuters) - TRANSGENE SA  TRNG.PA :
    * JULY 22, 2020 - TRANSGENE REPORTS RESULTS FROM CLINICAL
STUDY OF
TG4001 IN COMBINATION WITH AVELUMAB IN ADVANCED HPV-POSITIVE
CANCERS
    * EXPLORATORY PHASE 1B/2 TRIAL TARGETING A HETEROGENEOUS
POPULATION OF PATIENTS WITH HPV16- POSITIVE, RECURRENT AND/OR
METASTATIC CANCER WHOSE DISEASE HAS PROGRESSED AFTER UP TO THREE
LINES OF CHEMOTHERAPY, REPORTS PROMISING CLINICAL ACTIVITY WITH
COMBINATION REGIMEN
    * PATIENT FOLLOW-UP AND TRANSLATIONAL ANALYSES ARE ONGOING.
    * TRANSGENE INTENDS TO CONTINUE CLINICAL DEVELOPMENT OF
TG4001 IN
A LARGER, CONTROLLED CONFIRMATORY STUDY
    * PERFORMED POOLED ANALYSIS OF DATA FROM PHASE 1B/2 TRIAL
COMBINING TG4001, A HPV16 TARGETED THERAPEUTIC VACCINE, WITH
AVELUMAB (BAVENCIO®), HUMAN ANTI-PD-L1 ANTIBODY, IN
HPV16-POSITIVE RECURRENT AND/OR METASTATIC MALIGNANCIES
    * ANALYSIS CONFIRMS THAT TG4001 CAN BE SAFELY COMBINED WITH
IMMUNE
CHECKPOINT INHIBITOR AND SHOWS CLINICAL ACTIVITY OF THIS
COMBINATION REGIMEN

Source text for Eikon:  ID:nNDL4P4GLW 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))